Related Experiment Videos
[A clinical study on panipenem/betamipron in chronic respiratory tract infections]
S Odagiri1, M Matsumura, K Suzuki
1Department of Respiratory Diseases, Kanagawa Prefectural Cardiovascular and Respiratory Disease Center.
Abstract:
Panipenem/betamipron (CS-976, PAPM/BP), a new carbapenem antibiotic, was administered a single dose of 500 mg or 750 mg via intravenous drip infusion twice a day for treatment of chronic respiratory infection to study its clinical efficacy, bacteriological efficacy and safety. Twenty nine cases were studied for the efficacy evaluation. Only the safety evaluation was made in 6 cases which were judged to be unsuitable, because in some of them pneumonia and other diseases were not specified as the subject diseases, of serious illness in some the conditions were too serious, and in the other cases the duration of administration was insufficient since administration had to be discontinued due to side-effects. The duration of administration was 6 to 18 days with 1 g divided into 2 doses daily or 4 to 15 days with 1.5 g in 2 divided doses daily. When clinical efficacies were classified according to different diseases, this preparation was effective in 11 cases and slightly effective in 1 case of 12 cases of chronic bronchitis with an efficacy rate of 91.7%. It was effective in 10 cases, slightly effective in 1 case and ineffective in 1 case of 12 cases of bronchiectasis with an efficacy rate of 83.3%. It was slightly effective in 2 and ineffective in 1 out of 3 cases of diffuse panbronchiolitis, and was effective in 2 cases of pulmonary emphysema with infections. PAPM/BP was given at a dose level of 1 g in 2 divided doses daily to 17 cases and that of 1.5 g in 2 divided doses daily to 10 cases. For the remaining 2 cases, changes in the dose level were made in middle course of treatment. The efficacy rate in the 1 g regimen was 76.5% and that with the 1.5 g regimen was 90%. The overall results in the 29 cases included 23 effective, 4 slightly effective and 2 ineffective cases, thus the overall efficacy rate was 79.3%. As pathogens, 11 species including 24 strains were isolated and identified from 19 cases. They were Gram-positive cocci including 2 strains each of Staphylococcus aureus and Streptococcus pneumoniae, 1 strain each of Staphylococcus epidermidis, Streptococcus sanguis, and Streptococcus viridans and a strain of Streptococcus spp., and Gram-negative rods including 9 strains of Pseudomonas aeruginosa, 4 strains of Haemophilus influenzae and 1 strain each of Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas spp.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
Panipenem/betamipron demonstrated significant clinical efficacy in treating chronic respiratory infections, with overall effectiveness rates reaching 79.3%. This new carbapenem antibiotic showed promising results across various conditions like chronic bronchitis and bronchiectasis.
Area of Science:
- Pharmacology
- Infectious Diseases
Context:
- Chronic respiratory infections pose a significant health burden.
- Novel antibiotic development is crucial for combating resistant pathogens.
Purpose:
- To evaluate the clinical efficacy, bacteriological efficacy, and safety of panipenem/betamipron (PAPM/BP) in patients with chronic respiratory infections.
- To assess the effectiveness of PAPM/BP at different dosage regimens (1g and 1.5g daily).
Summary:
- A study involving 29 patients with chronic respiratory infections assessed the efficacy of panipenem/betamipron (PAPM/BP).
- The overall efficacy rate was 79.3%, with higher effectiveness observed at the 1.5g daily dosage regimen (90%) compared to the 1g regimen (76.5%).
- PAPM/BP showed particular efficacy in chronic bronchitis (91.7%) and bronchiectasis (83.3%).
Impact:
- Panipenem/betamipron represents a potentially valuable therapeutic option for managing chronic respiratory infections.
- Further research may explore its role in treating infections caused by identified pathogens such as Pseudomonas aeruginosa and Haemophilus influenzae.